GSK plc has entered into an agreement to license the worldwide rights for linerixibat, an experimental treatment for a rare liver disease, to the Italian pharmaceutical company Alfasigma. The deal, which could reach a total value of $690 million, focuses on addressing cholestatic pruritus, a condition that causes severe and persistent internal itching. This symptom is a hallmark of primary biliary cholangitis (PBC), an autoimmune disorder where the immune system attacks and damages the bile ducts within the liver.
GSK licenses liver drug to Alfasigma in $690 million deal
GSK is licensing its liver disease drug to Alfasigma in a deal worth up to $690 million. The agreement includes an initial $300 million upfront payment today.

Under the terms of the agreement, Alfasigma, which is based in Italy, will provide an upfront payment of $300 million to GSK. An additional $100 million is expected upon regulatory approval in the United States, which is anticipated by March 24. Furthermore, GSK will receive $20 million following approvals from regulators in the United Kingdom and the European Union.
In addition to these payments, GSK is eligible for up to $270 million in sales-based milestones and will earn tiered double-digit royalties on global sales. Alfasigma already maintains a significant international presence, marketing various liver disease treatments in more than 100 countries.











